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This work is funded by Asthma UK as part of the Asthma UK 
Centre for Applied Research [AUK-AC-2012-01].
Aims:
1. To identify the modifiable causes of non-adherence in children with PSA to inform an adherence 
intervention. 
2. To use the Medical Research Council (MRC) (Craig et al., 2008) guidance to develop an intervention 
for children with DA by tailoring support to overcome the perceptual and practical barriers to 
adhering to treatments, as recommended in the NICE Guidelines (Nunes et al., 2009).
Background:
• Problematic severe asthma (PSA) is defined as poorly controlled asthma despite 
high levels of prescribed medications (Bush et al., 2008)
• The prevalence in childhood is thought to be between 5-10% of asthmatic children; 
however the amount of resources these patients consume is disproportionately 
high
• PSA can be split into Difficult Asthma (DA) and Severe Therapy Resistant Asthma 
(STRA)
• DA is amenable to improvement by addressing relevant adherence, allergy and 
psychosocial issues. 
• At least 50% of paediatric patients with PSA are classified as DA; with non-
adherence being an issue for around half of these patients (Bracken et al., 2009).
Methods:
Study 1: Literature reviews
Literature Review: The known reasons for non-adherence in children with 
PSA 
Systematic Review: Effective components of previous asthma adherence 
interventions
Study 2: SmartInhaler Data
Secondary analysis will be conducted, using electronic monitoring 
(SmartInhaler) collected in over 100 children with asthma, to investigate 
patterns of non-adherence to inform the intervention. 
Study 3: A Mixed-Methods Cross-Sectional Study 
This study will use validated questionnaires and qualitative interviews 
with children and their parents to identify potentially modifiable factors 
associated with non-adherence.
Study 4: Intervention Development Group (IDG) 
A group consisting of researchers, clinicians and patients will be 
established.  The IDG will use the PhD results to develop the intervention 
manual.
Potential Implications:
This PhD addresses the crucial question of non-adherence in children with 
PSA.  
It is intended that the intervention developed will lead to a definitive multi-
site Randomised Control Trial and roll- out within the wider NHS.
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Maximise treatment benefits 
Feasibility/piloting
1. Testing procedures
2. Estimating 
recruitment/retention
3. Determining sample size
Evaluation
1. Assessing effectiveness
2. Understanding change process
3. Assessing cost-effectiveness
Implementation
1. Dissemination
2. Surveillance and monitoring
3. Long term follow-up
Development
1. Identifying the evidence base
2. Identifying/developing theory
3. Modelling process and outcomes
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Study 5: Feasibility and Acceptability
Finally, a feasibility and acceptability pilot study of the intervention will 
be conducted. 
Figure 1: Key stages from the MRC guidance for developing complex interventions
